Luye Pharma Reports Stable Share Capital and No Equity Movements in April 2026

Bulletin Express05-07

For the month ended 30 April 2026, Luye Pharma Group Ltd. reported no changes in either its authorised or issued share capital, according to the company’s monthly return filed with Hong Kong Exchanges and Clearing Ltd. on 7 May 2026.

Authorised share capital remained at 10.00 billion ordinary shares with a par value of USD 0.02 each, translating to USD 200.00 million.

Issued share capital was unchanged at 3.99 billion ordinary shares, and the company continued to hold zero treasury shares. As a result, total issued shares outstanding also stayed at 3.99 billion.

Luye Pharma confirmed compliance with the Main Board’s minimum public-float requirement of 25 percent.

Convertible bonds valued at USD 180.00 million (stock code: 05818) were outstanding, carrying a conversion price of HKD 4.88 and equivalent to 288.79 million potential new shares. No conversions took place during the month.

The company reported no share-option exercises, warrant activity, repurchases, or other equity-related transactions in April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136842288?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136842288","market":"us","top_or_hot":-1,"title":"Luye Pharma Reports Stable Share Capital and No Equity Movements in April 2026","media":"Bulletin Express","content":"<p>For the month ended 30 April 2026, Luye Pharma Group Ltd. reported no changes in either its authorised or issued share capital, according to the company’s monthly return filed with Hong Kong Exchanges and Clearing Ltd. on 7 May 2026.</p>\n<p>Authorised share capital remained at 10.00 billion ordinary shares with a par value of USD 0.02 each, translating to USD 200.00 million.</p>\n<p>Issued share capital was unchanged at 3.99 billion ordinary shares, and the company continued to hold zero treasury shares. As a result, total issued shares outstanding also stayed at 3.99 billion.</p>\n<p>Luye Pharma confirmed compliance with the Main Board’s minimum public-float requirement of 25 percent.</p>\n<p>Convertible bonds valued at USD 180.00 million (stock code: 05818) were outstanding, carrying a conversion price of HKD 4.88 and equivalent to 288.79 million potential new shares. No conversions took place during the month.</p>\n<p>The company reported no share-option exercises, warrant activity, repurchases, or other equity-related transactions in April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Luye Pharma Reports Stable Share Capital and No Equity Movements in April 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLuye Pharma Reports Stable Share Capital and No Equity Movements in April 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-07 16:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>For the month ended 30 April 2026, Luye Pharma Group Ltd. reported no changes in either its authorised or issued share capital, according to the company’s monthly return filed with Hong Kong Exchanges and Clearing Ltd. on 7 May 2026.</p>\n<p>Authorised share capital remained at 10.00 billion ordinary shares with a par value of USD 0.02 each, translating to USD 200.00 million.</p>\n<p>Issued share capital was unchanged at 3.99 billion ordinary shares, and the company continued to hold zero treasury shares. As a result, total issued shares outstanding also stayed at 3.99 billion.</p>\n<p>Luye Pharma confirmed compliance with the Main Board’s minimum public-float requirement of 25 percent.</p>\n<p>Convertible bonds valued at USD 180.00 million (stock code: 05818) were outstanding, carrying a conversion price of HKD 4.88 and equivalent to 288.79 million potential new shares. No conversions took place during the month.</p>\n<p>The company reported no share-option exercises, warrant activity, repurchases, or other equity-related transactions in April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02186","symbol_name":"绿叶制药","start_time":0,"source_url":"","article_id":"1136842288","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136842288","pubTimestamp":1778143516,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"For the month ended 30 April 2026, Luye Pharma Group Ltd. reported no changes in either its authorised or issued share capital, according to the company’s monthly return filed with Hong Kong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02186":"绿叶制药"},"translate_title":"绿叶制药2026年4月股本稳定无权益变动","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":1},"content_text":"For the month ended 30 April 2026, Luye Pharma Group Ltd. reported no changes in either its authorised or issued share capital, according to the company’s monthly return filed with Hong Kong Exchanges and Clearing Ltd. on 7 May 2026.\nAuthorised share capital remained at 10.00 billion ordinary shares with a par value of USD 0.02 each, translating to USD 200.00 million.\nIssued share capital was unchanged at 3.99 billion ordinary shares, and the company continued to hold zero treasury shares. As a result, total issued shares outstanding also stayed at 3.99 billion.\nLuye Pharma confirmed compliance with the Main Board’s minimum public-float requirement of 25 percent.\nConvertible bonds valued at USD 180.00 million (stock code: 05818) were outstanding, carrying a conversion price of HKD 4.88 and equivalent to 288.79 million potential new shares. No conversions took place during the month.\nThe company reported no share-option exercises, warrant activity, repurchases, or other equity-related transactions in April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136842288","isCrawlerRequest":true}